文献速递区域麻醉与超声术前评估与围术期医学

治疗剂量低分子肝素后24小时椎管内麻醉前血浆抗Xa活性残留研究

Residual anti-Xa activity in plasma of patients presenting for electively planned neuraxial regional anesthesia.
PubMed 文献 · Reg Anesth Pain Med · 2023-01-27

该回顾性队列分析纳入74例计划接受椎管内麻醉且术前使用治疗剂量低分子肝素的患者,发现末次给药24小时后18.0%的患者血浆抗Xa活性>0.2 IU/mL,提示现行24小时等待间隔可能不足以完全消除残留抗凝活性。

要点

  • 治疗剂量低分子肝素末次给药24小时后,18.0%患者抗Xa活性>0.2 IU/mL。
  • 末次给药时间与抗Xa水平仅呈弱相关,未发现其他危险因素。
  • 现行24小时等待间隔可能不足以完全排除残留抗凝活性。

核心结论

  • 治疗剂量低分子肝素末次给药24小时后,仍可测得预防范围的残留抗凝活性(抗Xa>0.2 IU/mL)。

研究设计与样本

  • 回顾性队列分析,纳入2015年4月1日至2020年4月1日弗莱堡大学医院74例计划椎管内麻醉前接受治疗剂量低分子肝素的患者。

主要发现

  • 末次治疗剂量低分子肝素给药24小时后,18.0%的患者血浆抗Xa活性>0.2 IU/mL。
  • 末次低分子肝素给药时间与血浆抗Xa水平之间呈弱相关,未发现其他危险因素。

关键数值与推荐

  • 主要终点为末次治疗剂量给药24小时后血浆抗Xa水平升高至预防范围或以上(>0.2 IU/mL)。

临床怎么用

  • 对接受治疗剂量低分子肝素的患者行椎管内麻醉前,应认识到24小时等待后仍可能存在残留抗凝活性。

局限性

  • 回顾性队列分析,样本量74例,单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the incidence of increased anti-Xa activity within plasma levels 24 hours after administration of therapeutic dose low-molecular-weight heparin in patients presenting for elective neuraxial anesthesia. BACKGROUND: Guidelines for neuroaxial regional anesthesia for patients with antithrombotic drugs recommend time intervals for waiting. There is scientific evidence to suggest that the recommended interval of 24 hours may be insufficient in patients treated with therapeutic dose low-molecular-weight heparin. METHODS: Retrospective cohort analysis of 74 patients who received therapeutic dose low-molecular-weight heparin before planned neuraxial anesthesia between April 1, 2015 and April 1, 2020 at Freiburg University Hospital. Primary endpoint was the occurrence of elevated plasma anti-Xa levels in prophylactic range or higher (>0.2 IU/mL) 24 hours after the last application of the therapeutic dose. RESULTS: 24 hours after the last dose of therapeutic low-molecular-weight heparin, 18.0% of patients had elevated anti-Xa activity levels >0.2 IU/mL. A weak correlation between the time since the last administration of low-molecular-weight heparin and plasma anti-Xa levels could be found. No other risk factors were seen. CONCLUSIONS: Relevant residual anticoagulant activity, as measured by plasma anti-Xa levels within a prophylactic range, is measurable 24 hours after the last administration of therapeutic dose low-molecular-weight heparin. TRIAL REGISTRATION NUMBER: German Clinical Trials Register DRKS00022099.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Knoerlein J, Brodbeck P, Büchsel M, et al. Residual anti-Xa activity in plasma of patients presenting for electively planned neuraxial regional anesthesia. Reg Anesth Pain Med. 2023. PMID: 36707225. doi:10.1136/rapm-2022-104079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。